Ibrutinib May Be Safe, Effective for Chronic Lymphocytic Leukemia with TP53 Aberrations
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, ibrutinib alone may be safe and effective for the first- or second-line treatment of patients with high-risk chronic lymphocytic leukemia (CLL) with TP53 aberrations.
For this single-arm, phase 2 study, researchers at the National Institutes of Health Clinical Center in Bethesda, Maryland, enrolled 47 patients with active CLL with deletion 17p13.1 and four patients with a TP53 aberration without a 17p13.1 deletion. Of those, 35 had previously untreated disease while 16 had relapsed or refractory CLL.
All patients received ibrutinib 420mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. Results showed that among the 33 evaluable previously untreated patients at 24 weeks, 97% (95% CI: 86-100) achieved an objective response. One patient had progressive disease.
Among the 15 evaluable patients with relapsed or refractory disease, 80% (95% CI: 52-96) achieved an objective response. In regard to safety, 24% of patients experienced severe neutropenia, 14% had severe anemia, and 10% experienced severe thrombocytopenia. Six percent of patients experienced grade 3 pneumonia and 2% had grade 3 rash.
The findings suggest that ibrutinib alone should be considered as an option for patients with high-risk CLL with TP53 aberrations for first- or second-line treatment.
Ibrutinib alone may be safe and effective for the first- or second-line treatment of CLL with TP53 aberrations.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer